JP2004518717A - 標的化された抗腫瘍剤送達系 - Google Patents

標的化された抗腫瘍剤送達系 Download PDF

Info

Publication number
JP2004518717A
JP2004518717A JP2002563960A JP2002563960A JP2004518717A JP 2004518717 A JP2004518717 A JP 2004518717A JP 2002563960 A JP2002563960 A JP 2002563960A JP 2002563960 A JP2002563960 A JP 2002563960A JP 2004518717 A JP2004518717 A JP 2004518717A
Authority
JP
Japan
Prior art keywords
cancer
administered
composition
anthracycline
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002563960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004518717A5 (https=
Inventor
デイビッド ジェイ． エマニュエル，
クレイグ エル． テンドラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2004518717A publication Critical patent/JP2004518717A/ja
Publication of JP2004518717A5 publication Critical patent/JP2004518717A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2002563960A 2001-02-09 2002-02-08 標的化された抗腫瘍剤送達系 Pending JP2004518717A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26780701P 2001-02-09 2001-02-09
PCT/US2002/004113 WO2002064168A1 (en) 2001-02-09 2002-02-08 Targetted anti-tumor drug delivery systems

Publications (2)

Publication Number Publication Date
JP2004518717A true JP2004518717A (ja) 2004-06-24
JP2004518717A5 JP2004518717A5 (https=) 2005-06-23

Family

ID=23020199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002563960A Pending JP2004518717A (ja) 2001-02-09 2002-02-08 標的化された抗腫瘍剤送達系

Country Status (7)

Country Link
US (1) US20020151508A1 (https=)
EP (1) EP1359942A1 (https=)
JP (1) JP2004518717A (https=)
CA (1) CA2437768A1 (https=)
MX (1) MXPA03007124A (https=)
PE (1) PE20020866A1 (https=)
WO (1) WO2002064168A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520082A (ja) * 2013-05-14 2016-07-11 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体投与計画
JP2016534039A (ja) * 2013-10-08 2016-11-04 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368013B (es) * 2001-02-19 2019-09-13 Novartis Ag Tratamiento de cáncer.
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
PL378812A1 (pl) * 2003-02-13 2006-05-29 Pfizer Products Inc. Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
CA2528545C (en) * 2003-06-13 2014-08-12 John Claude Savoir Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
CA2581133A1 (en) * 2004-09-20 2006-03-30 British Columbia Cancer Agency Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
KR100684380B1 (ko) 2005-05-24 2007-02-20 한국화학연구원 빗살형 폴리에틸렌글리콜을 결합한 리포솜 및 이의 제조방법
JP5333970B2 (ja) * 2007-03-20 2013-11-06 国立大学法人大阪大学 心筋梗塞の予防および／または治療薬
WO2014089127A1 (en) * 2012-12-03 2014-06-12 Merrimack Pharmaceuticals, Inc. Combination therapy for treating her2-positive cancers
EP3703731A4 (en) * 2017-11-04 2021-07-21 Aravive Biologics, Inc. METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
CZ20014083A3 (cs) * 1999-05-14 2002-08-14 Imclone Systems Incorporated Léčivo pro indikaci růstu refrakterních nádorů

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520082A (ja) * 2013-05-14 2016-07-11 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体投与計画
JP2023162436A (ja) * 2013-05-14 2023-11-08 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体投与計画
JP2016534039A (ja) * 2013-10-08 2016-11-04 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2019031568A (ja) * 2013-10-08 2019-02-28 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2021178847A (ja) * 2013-10-08 2021-11-18 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP7386208B2 (ja) 2013-10-08 2023-11-24 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン

Also Published As

Publication number Publication date
CA2437768A1 (en) 2002-08-22
EP1359942A1 (en) 2003-11-12
MXPA03007124A (es) 2003-11-18
PE20020866A1 (es) 2002-09-26
US20020151508A1 (en) 2002-10-17
WO2002064168A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
US11844795B2 (en) Combination therapy for cancer treatment
Motzer et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
CN109310754A (zh) 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
CN110051631A (zh) 使用含脂质体伊立替康的组合疗法治疗胰腺癌的方法
TW202521120A (zh) 藥物組合物及其應用
KR20200014298A (ko) Her2 양성 암의 치료
WO2021190637A1 (en) Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
JP2004518717A (ja) 標的化された抗腫瘍剤送達系
TW202425991A (zh) 阿森色替於治療癌症中之間歇性給藥方案
TW202133857A (zh) 用於乳癌治療之組合療法
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
TW202300153A (zh) 使用serd組合給藥方案治療癌症之方法
US20250352534A1 (en) Use of Niraparib for the Treatment of Brain Cancer
JP2023551968A (ja) タラゾパリブでの処置に対して感受性のある腫瘍を同定する方法およびその処置方法
TW202508598A (zh) 癌症療法
WO2025245463A9 (en) Combination therapies
TW202608446A (zh) 依維替定（ｅｃｕｂｅｃｔｅｄｉｎ）於包括與阿替利珠單抗的組合療法之癌症的治療中之用途
CN120035437A (zh) 用于治疗EGFR突变癌症的N-(1-((R)-1-丙烯酰基氮杂环庚烷-3-基)-7-氯-6-(((R)-四氢呋喃-3-基)氧基)-1H-苯并[d]咪唑-2-基)-2-甲基异烟酰胺(NX-019)
WO2023230429A1 (en) Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
WO2024216237A2 (en) Administration of a beta-catenin antagonist and methods of use
EP4213845A1 (en) New use of inhibitors of the notch signalling pathway
HK40124036A (zh) 治疗儿科患者的癌症的方法
CN111989107A (zh) 治疗儿科患者的癌症的方法
EA044960B1 (ru) Лечение her2-положительных злокачественных новообразований

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080107